tirzepatide gip agonist is a groundbreaking, once-weekly injectable medication that acts as a dual and GLP-1 receptor agonist. Marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, it mimics The dual agonist action of
Description
While compounded medications are not FDA-approved as brand-name products, they contain the identical active ingredient and are clinically equivalent when sourced from accredited facilities
10.1016/j.metabol.2024.156043 47 LoombaR.AbdelmalekM
Always consult your healthcare provider before starting, stopping, or changing any medication or treatment plan
GLP-1 RAs enhance or mimic the same functions in the body
Documentation of BMI and weight-related conditions is often required
